128 related articles for article (PubMed ID: 11213798)
1. Gene therapy of severe combined immunodeficiencies.
Fischer A; Hacein-Bey S; Le Deist F; Soudais C; Di Santo JP; de Saint Basile G; Cavazzana-Calvo M
Immunol Rev; 2000 Dec; 178():13-20. PubMed ID: 11213798
[TBL] [Abstract][Full Text] [Related]
2. Gene therapy of severe combined immunodeficiencies.
Cavazzana-Calvo M; Hacein-Bey S; Yates F; de Villartay JP; Le Deist F; Fischer A
J Gene Med; 2001; 3(3):201-6. PubMed ID: 11437325
[TBL] [Abstract][Full Text] [Related]
3. [Transplantation of genetically modified cells in the treatment of children with SCID: great hopes and recent disappointments].
Smogorzewska EM; Weinberg KI; Kohn DB
Med Wieku Rozwoj; 2003; 7(1):27-34. PubMed ID: 13130167
[TBL] [Abstract][Full Text] [Related]
4. Gene therapy for primary immunodeficiencies.
Fischer A; Hacein-Bey Abina S; Touzot F; Cavazzana M
Clin Genet; 2015 Dec; 88(6):507-15. PubMed ID: 25708106
[TBL] [Abstract][Full Text] [Related]
5. Gene therapy of severe combined immunodeficiencies.
Fischer A; Hacein-Bey S; Le Deist F; De Saint Basile G; Cavazzana-Calvo M
Adv Exp Med Biol; 2001; 495():199-204. PubMed ID: 11774567
[No Abstract] [Full Text] [Related]
6. Gene therapy of primary T cell immunodeficiencies.
Fischer A; Hacein-Bey-Abina S; Cavazzana-Calvo M
Gene; 2013 Aug; 525(2):170-3. PubMed ID: 23583799
[TBL] [Abstract][Full Text] [Related]
7. Gene therapy of severe combined immunodeficiencies.
Fischer A; Hacein-Bey S; Cavazzana-Calvo M
Nat Rev Immunol; 2002 Aug; 2(8):615-21. PubMed ID: 12154380
[TBL] [Abstract][Full Text] [Related]
8. Gene therapy for inherited immunodeficiency.
Touzot F; Hacein-Bey-Abina S; Fischer A; Cavazzana M
Expert Opin Biol Ther; 2014 Jun; 14(6):789-98. PubMed ID: 24823313
[TBL] [Abstract][Full Text] [Related]
9. [Gene therapy for hereditary immunodeficiencies].
Fischer A; de Saint-Basile G; Disanto JP; Hacein-Bey S; Sharara L; Cavazzana-Calvo M
C R Seances Soc Biol Fil; 1996; 190(1):77-93. PubMed ID: 8881271
[TBL] [Abstract][Full Text] [Related]
10. Gene therapy for primary adaptive immune deficiencies.
Fischer A; Hacein-Bey-Abina S; Cavazzana-Calvo M
J Allergy Clin Immunol; 2011 Jun; 127(6):1356-9. PubMed ID: 21624615
[TBL] [Abstract][Full Text] [Related]
11. Ten years of gene therapy for primary immune deficiencies.
Aiuti A; Roncarolo MG
Hematology Am Soc Hematol Educ Program; 2009; ():682-9. PubMed ID: 20008254
[TBL] [Abstract][Full Text] [Related]
12. Twenty-Five Years of Gene Therapy for ADA-SCID: From Bubble Babies to an Approved Drug.
Ferrua F; Aiuti A
Hum Gene Ther; 2017 Nov; 28(11):972-981. PubMed ID: 28847159
[TBL] [Abstract][Full Text] [Related]
13. Gene therapy for primary immunodeficiencies.
Fox TA; Booth C
Br J Haematol; 2021 Jun; 193(6):1044-1059. PubMed ID: 33336808
[TBL] [Abstract][Full Text] [Related]
14. Evolving Gene Therapy in Primary Immunodeficiency.
Thrasher AJ; Williams DA
Mol Ther; 2017 May; 25(5):1132-1141. PubMed ID: 28366768
[TBL] [Abstract][Full Text] [Related]
15. Adenosine deaminase deficiency as the first target disorder in gene therapy.
Onodera M; Sakiyama Y
Expert Opin Investig Drugs; 2000 Mar; 9(3):543-9. PubMed ID: 11060694
[TBL] [Abstract][Full Text] [Related]
16. Transfer of the ADA gene into bone marrow cells and peripheral blood lymphocytes for the treatment of patients affected by ADA-deficient SCID.
Bordignon C; Mavilio F; Ferrari G; Servida P; Ugazio AG; Notarangelo LD; Gilboa E; Rossini S; O'Reilly RJ; Smith CA
Hum Gene Ther; 1993 Aug; 4(4):513-20. PubMed ID: 8399494
[TBL] [Abstract][Full Text] [Related]
17. Outcomes in two Japanese adenosine deaminase-deficiency patients treated by stem cell gene therapy with no cytoreductive conditioning.
Otsu M; Yamada M; Nakajima S; Kida M; Maeyama Y; Hatano N; Toita N; Takezaki S; Okura Y; Kobayashi R; Matsumoto Y; Tatsuzawa O; Tsuchida F; Kato S; Kitagawa M; Mineno J; Hershfield MS; Bali P; Candotti F; Onodera M; Kawamura N; Sakiyama Y; Ariga T
J Clin Immunol; 2015 May; 35(4):384-98. PubMed ID: 25875699
[TBL] [Abstract][Full Text] [Related]
18. Treatment of severe combined immunodeficiency disease (SCID) due to adenosine deaminase deficiency with CD34+ selected autologous peripheral blood cells transduced with a human ADA gene. Amendment to clinical research project, Project 90-C-195, January 10, 1992.
Blaese RM; Culver KW; Chang L; Anderson WF; Mullen C; Nienhuis A; Carter C; Dunbar C; Leitman S; Berger M
Hum Gene Ther; 1993 Aug; 4(4):521-7. PubMed ID: 7691188
[TBL] [Abstract][Full Text] [Related]
19. Gene therapy techniques in the treatment of adenosine deaminase--deficiency severe combined immune deficiency syndrome.
Noonan NA; Senner AM
J Perinat Neonatal Nurs; 1994 Mar; 7(4):65-78. PubMed ID: 8151512
[TBL] [Abstract][Full Text] [Related]
20. Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy.
Hacein-Bey-Abina S; Le Deist F; Carlier F; Bouneaud C; Hue C; De Villartay JP; Thrasher AJ; Wulffraat N; Sorensen R; Dupuis-Girod S; Fischer A; Davies EG; Kuis W; Leiva L; Cavazzana-Calvo M
N Engl J Med; 2002 Apr; 346(16):1185-93. PubMed ID: 11961146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
